Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Chỉ hiển thị Multimedia

Gedatolisib-based regimens boost PFS in HR+/HER2– PIK3CA-WT ABC
21 May 2026
bởiElaine Soliven
Treatment with gedatolisib plus fulvestrant, with or without palbociclib, significantly improves progression-free survival (PFS) in patients with HR+/HER2– PIK3CA wild-type (WT) advanced breast cancer (ABC) compared with fulvestrant alone, according to the VIKTORIA-1 trial presented at ESMO Breast Cancer 2026.
21 May 2026

Capivasertib‒fulvestrant combo delays second progression, chemo in advanced breast cancer
20 May 2026
bởiStephen Padilla
The addition of capivasertib to fulvestrant improves time to second progression (PFS2) and time to first subsequent chemotherapy or death (TTFSC) in PIK3CA/AKT1/PTEN-altered patients with HR+/HER2- advanced breast cancer and the overall population, suggesting a clinically meaningful benefit when compared with placebo plus fulvestrant, as shown in the phase III CAPItello-291 trial.
20 May 2026






